Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373021 | 0.99 | ALOX5AP (0.87) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| Potassium Ion SCHEMBL3139013 | 0.99 | ALOX5AP (0.87) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2901372 | 0.99 | ALOX5AP (0.87) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL30585982 | 0.93 | ALOX5AP (1.00) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL13415377 | 0.93 | ALOX5AP (0.90) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL9535 | 0.93 | ALOX5AP (1.00) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL13415378 | 0.93 | ALOX5AP (0.90) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL3057387 | 0.93 | ALOX5AP (0.77) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2936036 | 0.93 | ALOX5AP (0.99) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL3259213 | 0.92 | ALOX5AP (0.77) | ALOX5APPTGS1CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697730-B2 | 5-lipoxygenase activating protein (FLAP) inhibitor | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2212312-A2 | 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR | Amira Pharmaceuticals, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20100075934-A1 | 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR | AMIRA PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009055721-A2 | 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR | AMIRA PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075934-A1 | 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITOR | ALOX5, ALOX5AP, LTA4H | ALOX5AP 2/4885PTGS1 61/4885CYP2C9 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.